{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:09:15Z","timestamp":1794244155224,"version":"4.9.0"},"reference-count":166,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100029408","name":"Theatre Bay Area","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100029408","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010721","name":"Ironwood Pharmaceuticals, Incorporated","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010721","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Ocular Surface"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jtos.2024.08.001","type":"journal-article","created":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T22:44:02Z","timestamp":1722638642000},"page":"213-224","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"special_numbering":"C","title":["Preservatives and ocular surface disease: A review"],"prefix":"10.1016","volume":"34","author":[{"given":"Malik Y.","family":"Kahook","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Rapuano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth M.","family":"Messmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan M.","family":"Radcliffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anat","family":"Galor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Baudouin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jtos.2024.08.001_bib1","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jtos.2017.05.008","article-title":"TFOS DEWS II definition and classification report","volume":"15","author":"Craig","year":"2017","journal-title":"Ocul Surf"},{"issue":"9","key":"10.1016\/j.jtos.2024.08.001_bib2","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1001\/archopht.118.9.1264","article-title":"Prevalence of and risk factors for dry eye syndrome","volume":"118","author":"Moss","year":"2000","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"10.1016\/j.jtos.2024.08.001_bib3","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1097\/ICO.0b013e3181c325b2","article-title":"Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications","volume":"29","author":"Fechtner","year":"2010","journal-title":"Cornea"},{"issue":"3","key":"10.1016\/j.jtos.2024.08.001_bib4","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jtos.2017.05.003","article-title":"TFOS DEWS II epidemiology report","volume":"15","author":"Stapleton","year":"2017","journal-title":"Ocul Surf"},{"issue":"11S","key":"10.1016\/j.jtos.2024.08.001_bib5","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.ophtha.2017.07.010","article-title":"The pathophysiology of dry eye disease: what we know and future directions for research","volume":"124","author":"Pflugfelder","year":"2017","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.jtos.2024.08.001_bib6","doi-asserted-by":"crossref","first-page":"e222","DOI":"10.1097\/OPX.0000000000000542","article-title":"Ocular surface disease in glaucoma: effect of polypharmacy and preservatives","volume":"92","author":"Ramli","year":"2015","journal-title":"Optom Vis Sci"},{"issue":"1","key":"10.1016\/j.jtos.2024.08.001_bib7","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1186\/s12886-021-02186-w","article-title":"\u03b2-blocker eye drops affect ocular surface through \u03b22 adrenoceptor of corneal limbal stem cells","volume":"21","author":"Yuan","year":"2021","journal-title":"BMC Ophthalmol"},{"issue":"1","key":"10.1016\/j.jtos.2024.08.001_bib8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/IJG.0b013e318264cd68","article-title":"Ocular surface disease exacerbated glaucoma: optimizing the ocular surface improves intraocular pressure control","volume":"23","author":"Batra","year":"2014","journal-title":"J Glaucoma"},{"issue":"3","key":"10.1016\/j.jtos.2024.08.001_bib9","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jtos.2017.05.011","article-title":"TFOS DEWS II pathophysiology report","volume":"15","author":"Bron","year":"2017","journal-title":"Ocul Surf"},{"issue":"9","key":"10.1016\/j.jtos.2024.08.001_bib10","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1097\/GME.0000000000001565","article-title":"Prevalence of ocular surface disease symptoms in peri- and postmenopausal women","volume":"27","author":"Garcia-Alfaro","year":"2020","journal-title":"Menopause"},{"key":"10.1016\/j.jtos.2024.08.001_bib11","series-title":"Ocular surface disease: cornea, conjunctiva and tear film: expert consult-online and print","author":"Holland","year":"2013"},{"issue":"6545","key":"10.1016\/j.jtos.2024.08.001_bib12","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1136\/bmj.293.6545.510-e","article-title":"Drug points: sicca syndrome associated with amiodarone therapy","volume":"293","author":"Dickinson","year":"1986","journal-title":"Br Med J"},{"issue":"2","key":"10.1016\/j.jtos.2024.08.001_bib13","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/15569527.2022.2050747","article-title":"Ocular manifestations of systemic isotretinoin in patients with acne: a systemic review and meta-analysis","volume":"41","author":"Elubous","year":"2022","journal-title":"Cutan Ocul Toxicol"},{"issue":"1","key":"10.1016\/j.jtos.2024.08.001_bib14","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2165\/00003495-200767010-00006","article-title":"Ocular adverse effects associated with systemic medications : recognition and management","volume":"67","author":"Santaella","year":"2007","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.jtos.2024.08.001_bib15","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.preteyeres.2010.03.001","article-title":"Preservatives in eyedrops: the good, the bad and the ugly","volume":"29","author":"Baudouin","year":"2010","journal-title":"Prog Retin Eye Res"},{"issue":"11S","key":"10.1016\/j.jtos.2024.08.001_bib16","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.ophtha.2017.05.031","article-title":"Meibomian gland disease: the role of gland dysfunction in dry eye disease","volume":"124","author":"Chhadva","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2024.08.001_bib17","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2147\/OPTH.S91402","article-title":"Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials","volume":"10","author":"Uusitalo","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jtos.2024.08.001_bib18","first-page":"623","article-title":"Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost","volume":"5","author":"Hommer","year":"2011","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jtos.2024.08.001_bib19","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/1240537","article-title":"Extracellular MMP-9-based assessment of ocular surface inflammation in patients with primary open-angle glaucoma","volume":"2019","author":"Zaleska-Zmijewska","year":"2019","journal-title":"J Ophthalmol"},{"issue":"1","key":"10.1016\/j.jtos.2024.08.001_bib20","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1111\/j.1755-3768.2012.02565.x","article-title":"Effects of SofZia-preserved travoprost and benzalkonium chloride-preserved latanoprost on the ocular surface -- a multicentre randomized single-masked study","volume":"91","author":"Aihara","year":"2013","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jtos.2024.08.001_bib21","first-page":"291","article-title":"Effects of prostaglandin analog therapy on the ocular surface of glaucoma patients","volume":"3","author":"Horsley","year":"2009","journal-title":"Clin Ophthalmol"},{"issue":"5","key":"10.1016\/j.jtos.2024.08.001_bib22","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1517\/14740338.2015.1017467","article-title":"From benzalkonium chloride-preserved Latanoprost to Polyquad-preserved Travoprost: a 6-month study on ocular surface safety and tolerability","volume":"14","author":"Rossi","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.jtos.2024.08.001_bib23","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/603782","article-title":"Influence of BAK-preserved prostaglandin analog treatment on the ocular surface health in patients with newly diagnosed primary open-angle glaucoma","volume":"2013","author":"Tomic","year":"2013","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.jtos.2024.08.001_bib24","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.2147\/OPTH.S176605","article-title":"Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study","volume":"12","author":"Economou","year":"2018","journal-title":"Clin Ophthalmol"},{"issue":"10","key":"10.1016\/j.jtos.2024.08.001_bib25","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jfo.2018.04.012","article-title":"Efficacy and safety of preservative-free timolol 0.1% gel in open-angle glaucoma and ocular hypertension in treatment-naive patients and patients intolerant to other hypotensive medications","volume":"41","author":"Lazreg","year":"2018","journal-title":"J Fr Ophtalmol"},{"issue":"6","key":"10.1016\/j.jtos.2024.08.001_bib26","doi-asserted-by":"crossref","first-page":"e610","DOI":"10.1097\/IJG.0000000000000265","article-title":"Effect of switching to travoprost preserved with SofZia in glaucoma patients with chronic superficial punctate keratitis while receiving BAK-preserved latanoprost","volume":"25","author":"Aihara","year":"2016","journal-title":"J Glaucoma"},{"issue":"6","key":"10.1016\/j.jtos.2024.08.001_bib27","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1097\/IJG.0000000000000020","article-title":"Safety and efficacy of benzalkonium chloride-optimized tafluprost in Japanese glaucoma patients with existing superficial punctate keratitis","volume":"24","author":"Suzuki","year":"2015","journal-title":"J Glaucoma"},{"issue":"3","key":"10.1016\/j.jtos.2024.08.001_bib28","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jtos.2017.05.001","article-title":"TFOS DEWS II diagnostic methodology report","volume":"15","author":"Wolffsohn","year":"2017","journal-title":"Ocul Surf"},{"issue":"1","key":"10.1016\/j.jtos.2024.08.001_bib29","first-page":"52","article-title":"Ocular surface evaluation after the substitution of benzalkonium chloride preserved prostaglandin eye drops by a preservative-free prostaglandin analogue","volume":"8","author":"Lopes","year":"2019","journal-title":"Med Hypothesis Discov Innov Ophthalmol"},{"issue":"3","key":"10.1016\/j.jtos.2024.08.001_bib30","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ajo.2006.11.060","article-title":"Impact of dry eye syndrome on vision-related quality of life","volume":"143","author":"Miljanovic","year":"2007","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.jtos.2024.08.001_bib31","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.ajo.2013.12.023","article-title":"Dry eye in the beaver dam offspring study: prevalence, risk factors, and health-related quality of life","volume":"157","author":"Paulsen","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2024.08.001_bib32","doi-asserted-by":"crossref","DOI":"10.21037\/aes-22-35","article-title":"A narrative review of limbal stem cell deficiency & severe ocular surface disease","volume":"8","author":"Hu","year":"2023","journal-title":"Ann Eye Sci"},{"key":"10.1016\/j.jtos.2024.08.001_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.exer.2020.108294","article-title":"Inflammatory basis for dry eye disease flares","volume":"201","author":"Perez","year":"2020","journal-title":"Exp Eye Res"},{"issue":"3","key":"10.1016\/j.jtos.2024.08.001_bib34","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/eye.2014.263","article-title":"Neuropathic ocular pain: an important yet underevaluated feature of dry eye","volume":"29","author":"Galor","year":"2015","journal-title":"Eye (Lond)"},{"issue":"3","key":"10.1016\/j.jtos.2024.08.001_bib35","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jtos.2017.05.002","article-title":"TFOS DEWS II pain and sensation report","volume":"15","author":"Belmonte","year":"2017","journal-title":"Ocul Surf"},{"issue":"3","key":"10.1016\/j.jtos.2024.08.001_bib36","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jtos.2017.05.004","article-title":"TFOS DEWS II iatrogenic report","volume":"15","author":"Gomes","year":"2017","journal-title":"Ocul Surf"},{"issue":"3","key":"10.1016\/j.jtos.2024.08.001_bib37","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1089\/jop.2010.0133","article-title":"Symptoms and signs of tear film dysfunction in glaucomatous patients","volume":"27","author":"Valente","year":"2011","journal-title":"J Ocul Pharmacol Therapeut"},{"issue":"1","key":"10.1016\/j.jtos.2024.08.001_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ajo.2011.05.033","article-title":"Ocular surface disease and quality of life in patients with glaucoma","volume":"153","author":"Skalicky","year":"2012","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.jtos.2024.08.001_bib39","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/IJG.0b013e31815c5f4f","article-title":"Prevalence of ocular surface disease in glaucoma patients","volume":"17","author":"Leung","year":"2008","journal-title":"J Glaucoma"},{"issue":"9","key":"10.1016\/j.jtos.2024.08.001_bib40","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1097\/ICO.0b013e31823f8cb6","article-title":"Tear film osmolarity in patients treated for glaucoma or ocular hypertension","volume":"31","author":"Labbe","year":"2012","journal-title":"Cornea"},{"issue":"3","key":"10.1016\/j.jtos.2024.08.001_bib41","doi-asserted-by":"crossref","first-page":"296","DOI":"10.5301\/ejo.5000220","article-title":"Risk factors to develop ocular surface disease in treated glaucoma or ocular hypertension patients","volume":"23","author":"Rossi","year":"2013","journal-title":"Eur J Ophthalmol"},{"issue":"1","key":"10.1016\/j.jtos.2024.08.001_bib42","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/ICL.0000000000000544","article-title":"Ocular surface disease and glaucoma medications: a clinical approach","volume":"45","author":"Zhang","year":"2019","journal-title":"Eye Contact Lens"},{"issue":"1","key":"10.1016\/j.jtos.2024.08.001_bib43","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0002-9394(14)73757-2","article-title":"Decreased basal tear turnover in patients with untreated primary open-angle glaucoma","volume":"120","author":"Kuppens","year":"1995","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2024.08.001_bib44","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ajo.2021.06.015","article-title":"Corticosteroid pulse therapy for Stevens-Johnson syndrome and toxic epidermal necrolysis patients with acute ocular involvement","volume":"231","author":"Mieno","year":"2021","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jtos.2024.08.001_bib45","first-page":"441","article-title":"A multicenter evaluation of ocular surface disease prevalence in patients with glaucoma","volume":"6","author":"Garcia-Feijoo","year":"2012","journal-title":"Clin Ophthalmol"},{"issue":"11","key":"10.1016\/j.jtos.2024.08.001_bib46","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1001\/archopht.1994.01090230060021","article-title":"Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery","volume":"112","author":"Broadway","year":"1994","journal-title":"Arch Ophthalmol"},{"issue":"11","key":"10.1016\/j.jtos.2024.08.001_bib47","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s00417-008-0881-9","article-title":"German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye","volume":"246","author":"Erb","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"10.1016\/j.jtos.2024.08.001_bib48","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1177\/112067210901900409","article-title":"Dry eye syndrome-related quality of life in glaucoma patients","volume":"19","author":"Rossi","year":"2009","journal-title":"Eur J Ophthalmol"},{"issue":"1","key":"10.1016\/j.jtos.2024.08.001_bib49","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1586\/17469899.4.1.59","article-title":"Preservatives in topical ophthalmic medications: historical and clinical perspectives","volume":"4","author":"Freeman","year":"2014","journal-title":"Expert Rev Ophthalmol"},{"issue":"2","key":"10.1016\/j.jtos.2024.08.001_bib50","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41433-021-01668-x","article-title":"Ocular benzalkonium chloride exposure: problems and solutions","volume":"36","author":"Goldstein","year":"2022","journal-title":"Eye (Lond)"},{"issue":"10","key":"10.1016\/j.jtos.2024.08.001_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026103","article-title":"Corneal alternations induced by topical application of benzalkonium chloride in rabbit","volume":"6","author":"Chen","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jtos.2024.08.001_bib52","doi-asserted-by":"crossref","first-page":"34","DOI":"10.5301\/ejo.5000001","article-title":"Comparison of a travoprost BAK-free formulation preserved with polyquaternium-1 with BAK-preserved travoprost in ocular hypertension or open-angle glaucoma","volume":"22","author":"Gandolfi","year":"2012","journal-title":"Eur J Ophthalmol"},{"issue":"7","key":"10.1016\/j.jtos.2024.08.001_bib53","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jfo.2016.05.006","article-title":"[Unpreserved latanoprost in the treatment of open-angle glaucoma and ocular hypertension. A multicenter, randomized, controlled study]","volume":"39","author":"Denis","year":"2016","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.jtos.2024.08.001_bib54","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/1471-2415-14-151","article-title":"Late-day intraocular pressure-lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial","volume":"14","author":"DuBiner","year":"2014","journal-title":"BMC Ophthalmol"},{"issue":"9","key":"10.1016\/j.jtos.2024.08.001_bib55","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/eye.2011.134","article-title":"Travoprost 0.004%\/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy","volume":"25","author":"Kitazawa","year":"2011","journal-title":"Eye (Lond)"},{"issue":"6","key":"10.1016\/j.jtos.2024.08.001_bib56","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s12325-014-0125-9","article-title":"24-hour efficacy of travoprost\/timolol BAK-free versus latanoprost\/timolol fixed combinations in patients insufficiently controlled with latanoprost","volume":"31","author":"Konstas","year":"2014","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtos.2024.08.001_bib57","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s12886-015-0151-7","article-title":"Effect of benzalkonium chloride-free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study","volume":"15","author":"Lopes","year":"2015","journal-title":"BMC Ophthalmol"},{"issue":"6","key":"10.1016\/j.jtos.2024.08.001_bib58","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1089\/jop.2015.0159","article-title":"Effect of travoprost and nonsteroidal anti-inflammatory drug on diurnal intraocular pressure in normal subjects with low-teen baseline intraocular pressure","volume":"32","author":"Sakata","year":"2016","journal-title":"J Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.jtos.2024.08.001_bib59","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.2147\/OPTH.S367756","article-title":"Open-label extension study comparing latanoprost 0.005% without vs with benzalkonium chloride in open-angle glaucoma or ocular hypertension","volume":"16","author":"Shen Lee","year":"2022","journal-title":"Clin Ophthalmol"},{"issue":"8","key":"10.1016\/j.jtos.2024.08.001_bib61","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1136\/bjophthalmol-2012-303040","article-title":"Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial","volume":"97","author":"Day","year":"2013","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"10.1016\/j.jtos.2024.08.001_bib62","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jfo.2010.06.018","article-title":"[Preservatives in eye drops: toward awareness of their toxicity]","volume":"33","author":"Vaede","year":"2010","journal-title":"J Fr Ophtalmol"},{"issue":"1","key":"10.1016\/j.jtos.2024.08.001_bib63","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/bjo.82.1.39","article-title":"Short-term comparative study of topical 2% carteolol with and without benzalkonium chloride in healthy volunteers","volume":"82","author":"Baudouin","year":"1998","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.jtos.2024.08.001_bib64","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jtos.2013.07.003","article-title":"Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meeting","volume":"11","author":"Baudouin","year":"2013","journal-title":"Ocul Surf"},{"issue":"11","key":"10.1016\/j.jtos.2024.08.001_bib65","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s12325-010-0070-1","article-title":"Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells","volume":"27","author":"Ammar","year":"2010","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtos.2024.08.001_bib66","doi-asserted-by":"crossref","first-page":"919","DOI":"10.2147\/OPTH.S13406","article-title":"Cytotoxicity of prostaglandin analog eye drops preserved with benzalkonium chloride in multiple corneoconjunctival cell lines","volume":"4","author":"Ayaki","year":"2010","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jtos.2024.08.001_bib67","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.2147\/OPTH.S13708","article-title":"Toxicity of antiglaucoma drugs with and without benzalkonium chloride to cultured human corneal endothelial cells","volume":"4","author":"Ayaki","year":"2010","journal-title":"Clin Ophthalmol"},{"issue":"4","key":"10.1016\/j.jtos.2024.08.001_bib68","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3341\/kjo.2015.29.4.270","article-title":"In vivo effects of preservative-free and preserved prostaglandin analogs: mouse ocular surface study","volume":"29","author":"Kim","year":"2015","journal-title":"Korean J Ophthalmol"},{"issue":"2","key":"10.1016\/j.jtos.2024.08.001_bib69","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/ICO.0000000000000695","article-title":"Comparison of the efficacy of fluorometholone with and without benzalkonium chloride in ocular surface disease","volume":"35","author":"Kim","year":"2016","journal-title":"Cornea"},{"issue":"9","key":"10.1016\/j.jtos.2024.08.001_bib70","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1089\/jop.2014.0030","article-title":"In vitro effects of preserved and unpreserved anti-allergic drugs on human corneal epithelial cells","volume":"30","author":"Guzman-Aranguez","year":"2014","journal-title":"J Ocul Pharmacol Therapeut"},{"key":"10.1016\/j.jtos.2024.08.001_bib71","first-page":"745","article-title":"Multiple endpoint analysis of BAC-preserved and unpreserved antiallergic eye drops on a 3D-reconstituted corneal epithelial model","volume":"17","author":"Pauly","year":"2011","journal-title":"Mol Vis"},{"issue":"10","key":"10.1016\/j.jtos.2024.08.001_bib72","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1136\/bjophthalmol-2011-300012","article-title":"Effects of glaucoma medications and preservatives on cultured human trabecular meshwork and non-pigmented ciliary epithelial cell lines","volume":"95","author":"Ammar","year":"2011","journal-title":"Br J Ophthalmol"},{"issue":"9","key":"10.1016\/j.jtos.2024.08.001_bib73","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1007\/s10792-018-1051-7","article-title":"BKC and CME: is benzalkonium chloride hindering our efforts to achieve the desired postoperative visual acuity?","volume":"39","author":"Sethi","year":"2019","journal-title":"Int Ophthalmol"},{"issue":"11","key":"10.1016\/j.jtos.2024.08.001_bib74","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050180","article-title":"A new safety concern for glaucoma treatment demonstrated by mass spectrometry imaging of benzalkonium chloride distribution in the eye, an experimental study in rabbits","volume":"7","author":"Brignole-Baudouin","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jtos.2024.08.001_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100916","article-title":"Inflammation in glaucoma: from the back to the front of the eye, and beyond","volume":"83","author":"Baudouin","year":"2021","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.jtos.2024.08.001_bib76","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.aanat.2018.12.003","article-title":"In vitro effects of benzalkonium chloride and prostaglandins on human meibomian gland epithelial cells","volume":"222","author":"Rath","year":"2019","journal-title":"Ann Anat"},{"key":"10.1016\/j.jtos.2024.08.001_bib77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mrfmmm.2014.11.006","article-title":"Genomic and post-genomic effects of anti-glaucoma drugs preservatives in trabecular meshwork","volume":"772","author":"Izzotti","year":"2015","journal-title":"Mutat Res"},{"issue":"2","key":"10.1016\/j.jtos.2024.08.001_bib78","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000335984","article-title":"Reduced in vivo ocular surface toxicity with polyquad-preserved travoprost versus benzalkonium-preserved travoprost or latanoprost ophthalmic solutions","volume":"48","author":"Liang","year":"2012","journal-title":"Ophthalmic Res"},{"issue":"8","key":"10.1016\/j.jtos.2024.08.001_bib79","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s12325-008-0078-y","article-title":"Quantitative analysis of conjunctival goblet cells after chronic application of topical drops","volume":"25","author":"Kahook","year":"2008","journal-title":"Adv Ther"},{"issue":"3","key":"10.1016\/j.jtos.2024.08.001_bib80","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/ICO.0b013e31815cf651","article-title":"Comparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tears","volume":"27","author":"Kahook","year":"2008","journal-title":"Cornea"},{"issue":"5","key":"10.1016\/j.jtos.2024.08.001_bib81","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1089\/jop.2008.0140","article-title":"Evaluation of biomarkers of inflammation in response to benzalkonium chloride on corneal and conjunctival epithelial cells","volume":"25","author":"Epstein","year":"2009","journal-title":"J Ocul Pharmacol Therapeut"},{"issue":"7","key":"10.1016\/j.jtos.2024.08.001_bib82","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/S0161-6420(92)31847-0","article-title":"Ocular surface alteration after long-term treatment with an antiglaucomatous drug","volume":"99","author":"Herreras","year":"1992","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jtos.2024.08.001_bib83","first-page":"415","article-title":"Impact of short-term exposure of commercial eyedrops preserved with benzalkonium chloride on precorneal mucin","volume":"12","author":"Chung","year":"2006","journal-title":"Mol Vis"},{"issue":"11","key":"10.1016\/j.jtos.2024.08.001_bib84","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1136\/bjo.2006.094912","article-title":"Trefoil factor family 1, MUC5AC and human leucocyte antigen-DR expression by conjunctival cells in patients with glaucoma treated with chronic drugs: could these markers predict the success of glaucoma surgery?","volume":"90","author":"Souchier","year":"2006","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"10.1016\/j.jtos.2024.08.001_bib85","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/IJG.0b013e3181d9ccb0","article-title":"Conjunctival inflammatory cells and their predictive role for deep sclerectomy in primary open-angle glaucoma and exfoliation glaucoma","volume":"20","author":"Helin","year":"2011","journal-title":"J Glaucoma"},{"issue":"13","key":"10.1016\/j.jtos.2024.08.001_bib86","doi-asserted-by":"crossref","first-page":"5406","DOI":"10.1167\/iovs.16-20662","article-title":"Author Response: in vivo goblet cell density as a potential indicator of glaucoma filtration surgery outcome [letter to the editor]","volume":"57","author":"Agnifili","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"10.1016\/j.jtos.2024.08.001_bib87","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1159\/000027457","article-title":"Effect of conjunctival structure and inflammatory cell counts on intraocular pressure after trabeculectomy","volume":"213","author":"Arici","year":"1999","journal-title":"Ophthalmologica"},{"issue":"6","key":"10.1016\/j.jtos.2024.08.001_bib88","doi-asserted-by":"crossref","first-page":"BIO114","DOI":"10.1167\/iovs.17-21795","article-title":"In vivo confocal imaging of the conjunctiva as a predictive tool for the glaucoma filtration surgery outcome","volume":"58","author":"Mastropasqua","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jtos.2024.08.001_bib89","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/460483","article-title":"The effects of topical antiglaucoma drugs as monotherapy on the ocular surface: a prospective study","volume":"2014","author":"Aydin Kurna","year":"2014","journal-title":"J Ophthalmol"},{"issue":"5","key":"10.1016\/j.jtos.2024.08.001_bib90","doi-asserted-by":"crossref","first-page":"e397","DOI":"10.1111\/aos.12131","article-title":"Conjunctival goblet cells density and preservative-free tafluprost therapy for glaucoma: an in vivo confocal microscopy and impression cytology study","volume":"91","author":"Mastropasqua","year":"2013","journal-title":"Acta Ophthalmol"},{"issue":"10","key":"10.1016\/j.jtos.2024.08.001_bib91","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.6061\/clinics\/2013(10)05","article-title":"Ocular surface evaluation in patients treated with a fixed combination of prostaglandin analogues with 0.5% timolol maleate topical monotherapy: a randomized clinical trial","volume":"68","author":"Russ","year":"2013","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.jtos.2024.08.001_bib92","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/165475","article-title":"Effects of long-term antiglaucoma eye drops on conjunctival structures: an in vivo confocal microscopy study","volume":"2015","author":"Zhu","year":"2015","journal-title":"J Ophthalmol"},{"issue":"4","key":"10.1016\/j.jtos.2024.08.001_bib93","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0377-1237(07)80011-6","article-title":"Ocular surface changes in primary open angle glaucoma with long term topical anti glaucoma medication","volume":"63","author":"Kamath","year":"2007","journal-title":"Med J Armed Forces India"},{"issue":"4","key":"10.1016\/j.jtos.2024.08.001_bib94","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.jtos.2017.03.004","article-title":"Tear cytokine profile of glaucoma patients treated with preservative-free or preserved latanoprost","volume":"15","author":"Martinez-de-la-Casa","year":"2017","journal-title":"Ocul Surf"},{"issue":"12","key":"10.1016\/j.jtos.2024.08.001_bib95","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.ophtha.2004.06.023","article-title":"Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term","volume":"111","author":"Baudouin","year":"2004","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.jtos.2024.08.001_bib96","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1038\/cdd.2008.95","article-title":"The chemokine CXCL12 promotes survival of postmitotic neurons by regulating Rb protein","volume":"15","author":"Khan","year":"2008","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.jtos.2024.08.001_bib97","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.tiv.2017.02.006","article-title":"Effect of benzalkonium chloride on trabecular meshwork cells in a new in vitro 3D trabecular meshwork model for glaucoma","volume":"41","author":"Bouchemi","year":"2017","journal-title":"Toxicol In Vitro"},{"issue":"3","key":"10.1016\/j.jtos.2024.08.001_bib98","doi-asserted-by":"crossref","first-page":"156","DOI":"10.4068\/cmj.2019.55.3.156","article-title":"Effects of preservative on the meibomian gland in glaucoma patients treated with prostaglandin analogues","volume":"55","author":"Ha","year":"2019","journal-title":"Chonnam Med J"},{"issue":"4","key":"10.1016\/j.jtos.2024.08.001_bib99","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.ajo.2008.10.019","article-title":"An in vivo confocal microscopy analysis of effects of topical antiglaucoma therapy with preservative on corneal innervation and morphology","volume":"147","author":"Martone","year":"2009","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"10.1016\/j.jtos.2024.08.001_bib100","first-page":"931","article-title":"Ocular surface evaluation in eyes with chronic glaucoma on long term topical antiglaucoma therapy","volume":"10","author":"Saini","year":"2017","journal-title":"Int J Ophthalmol"},{"issue":"5","key":"10.1016\/j.jtos.2024.08.001_bib101","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/archopht.118.5.615","article-title":"Reliability and validity of the Ocular Surface Disease Index","volume":"118","author":"Schiffman","year":"2000","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"10.1016\/j.jtos.2024.08.001_bib102","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4274\/tjo.galenos.2019.29000","article-title":"Correlation of ocular surface disease and quality of life in Indian glaucoma patients: BAC-preserved versus BAC-free travoprost","volume":"50","author":"Kumar","year":"2020","journal-title":"Turk J Ophthalmol"},{"issue":"3","key":"10.1016\/j.jtos.2024.08.001_bib103","doi-asserted-by":"crossref","first-page":"249","DOI":"10.22336\/rjo.2019.38","article-title":"Ocular surface disease with BAK preserved travoprost and polyquaternium 1(Polyquad) preserved travoprost","volume":"63","author":"Kumar","year":"2019","journal-title":"Rom J Ophthalmol"},{"issue":"12","key":"10.1016\/j.jtos.2024.08.001_bib104","doi-asserted-by":"crossref","first-page":"8111","DOI":"10.1167\/iovs.14-14504","article-title":"Benzalkonium chloride induces subconjunctival fibrosis through the COX-2-modulated activation of a TGF-\u03b21\/Smad3 signaling pathway","volume":"55","author":"Huang","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10.1016\/j.jtos.2024.08.001_bib105","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S0161-6420(99)90116-1","article-title":"Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies","volume":"106","author":"Baudouin","year":"1999","journal-title":"Ophthalmology"},{"issue":"3","key":"10.1016\/j.jtos.2024.08.001_bib106","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0161-6420(89)32888-0","article-title":"Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon's capsule in glaucomatous patients","volume":"96","author":"Sherwood","year":"1989","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.jtos.2024.08.001_bib107","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/aos.12550","article-title":"Conjunctival matrix metalloproteinases and their inhibitors in glaucoma patients","volume":"93","author":"Helin-Toiviainen","year":"2015","journal-title":"Acta Ophthalmol"},{"issue":"8","key":"10.1016\/j.jtos.2024.08.001_bib108","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1055\/s-0032-1328410","article-title":"Immunoassay for matrix metalloproteinase-9 in the tear film of patients with pseudoexfoliation syndrome - a pilot study. Article in German","volume":"230","author":"Zimmermann","year":"2013","journal-title":"Klin Monbl Augenheilkd"},{"issue":"7","key":"10.1016\/j.jtos.2024.08.001_bib109","doi-asserted-by":"crossref","first-page":"e876","DOI":"10.1111\/aos.14410","article-title":"Preservative-free versus preserved glaucoma eye drops and occurrence of glaucoma surgery. A retrospective study based on the French national health insurance information system, 2008-2016","volume":"98","author":"Chamard","year":"2020","journal-title":"Acta Ophthalmol"},{"issue":"9","key":"10.1016\/j.jtos.2024.08.001_bib110","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1097\/IJG.0b013e31825af67d","article-title":"Preservative exposure and surgical outcomes in glaucoma patients: the PESO study","volume":"22","author":"Boimer","year":"2013","journal-title":"J Glaucoma"},{"issue":"11","key":"10.1016\/j.jtos.2024.08.001_bib111","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1001\/archopht.1990.01070130045027","article-title":"The influence of prior therapy on the success of trabeculectomy","volume":"108","author":"Lavin","year":"1990","journal-title":"Arch Ophthalmol"},{"issue":"9","key":"10.1016\/j.jtos.2024.08.001_bib112","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1136\/bjo.77.9.590","article-title":"Adverse effects of topical antiglaucomatous medications on the conjunctiva","volume":"77","author":"Broadway","year":"1993","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jtos.2024.08.001_bib113","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1159\/000334791","article-title":"Ocular surface and external filtration surgery: mutual relationships","volume":"50","author":"Baudouin","year":"2012","journal-title":"Dev Ophthalmol"},{"issue":"3","key":"10.1016\/j.jtos.2024.08.001_bib114","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/IJG.0b013e3181d9ccb0","article-title":"Conjunctival inflammatory cells and their predictive role for deep sclerectomy in primary open-angle glaucoma and exfoliation glaucoma","volume":"20","author":"Helin","year":"2011","journal-title":"J Glaucoma"},{"issue":"7","key":"10.1016\/j.jtos.2024.08.001_bib115","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.ophtha.2007.10.024","article-title":"Filtering blebs and aqueous pathway an immunocytological and in vivo confocal microscopy study","volume":"115","author":"Amar","year":"2008","journal-title":"Ophthalmology"},{"issue":"7","key":"10.1016\/j.jtos.2024.08.001_bib116","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1167\/iovs.16-19257","article-title":"In vivo goblet cell density as a potential indicator of glaucoma filtration surgery outcome","volume":"57","author":"Agnifili","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"10.1016\/j.jtos.2024.08.001_bib117","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3109\/02713683.2010.547648","article-title":"Long-term topical antiglaucoma medications cause enhanced Tenon\u2019s capsule fibroblast proliferation and abnormal TGF-\u03b2 and MMP expressions: potential effects on glaucoma filtering surgery","volume":"36","author":"Leng","year":"2011","journal-title":"Curr Eye Res"},{"issue":"2","key":"10.1016\/j.jtos.2024.08.001_bib118","doi-asserted-by":"crossref","DOI":"10.1177\/11206721221144339","article-title":"Ocular surface disease signs and symptoms of glaucoma patients and their relation to glaucoma medication in Finland","volume":"33","author":"Parkkari","year":"2022","journal-title":"Eur J Ophthalmol"},{"issue":"13","key":"10.1016\/j.jtos.2024.08.001_bib119","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10132897","article-title":"Ocular comorbidities in rosacea: a case-control study based on seven institutions","volume":"10","author":"Woo","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.jtos.2024.08.001_bib120","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.2147\/OPTH.S211611","article-title":"The use of preservatives in dry eye drops","volume":"13","author":"Walsh","year":"2019","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"10.1016\/j.jtos.2024.08.001_bib121","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/bjophthalmol-2012-302121","article-title":"Efficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucoma","volume":"97","author":"Rouland","year":"2013","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"10.1016\/j.jtos.2024.08.001_bib122","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/IJG.0000000000001248","article-title":"Noninferiority of preservative-free versus BAK-preserved latanoprost-timolol fixed combination eye drops in patients with open-angle glaucoma or ocular hypertension","volume":"28","author":"Aptel","year":"2019","journal-title":"J Glaucoma"},{"issue":"1","key":"10.1016\/j.jtos.2024.08.001_bib123","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12886-017-0453-z","article-title":"Efficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients: a prospective crossover study","volume":"17","author":"Lee","year":"2017","journal-title":"BMC Ophthalmol"},{"issue":"3","key":"10.1016\/j.jtos.2024.08.001_bib124","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/ceo.12431","article-title":"Clinical audit examining the impact of benzalkonium chloride-free anti-glaucoma medications on patients with symptoms of ocular surface disease","volume":"43","author":"Goldberg","year":"2015","journal-title":"Clin Exp Ophthalmol"},{"issue":"1","key":"10.1016\/j.jtos.2024.08.001_bib125","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/15569527.2019.1680685","article-title":"Preservative-free versus preserved brimonidine %0.15 preparations in the treatment of glaucoma and ocular hypertension: short term evaluation of efficacy, safety, and potential advantages","volume":"39","author":"Duru","year":"2020","journal-title":"Cutan Ocul Toxicol"},{"key":"10.1016\/j.jtos.2024.08.001_bib126","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.2147\/OPTH.S103084","article-title":"Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice","volume":"10","author":"Pillunat","year":"2016","journal-title":"Clin Ophthalmol"},{"issue":"8","key":"10.1016\/j.jtos.2024.08.001_bib127","first-page":"1251","article-title":"Efficacy and safety of bimatoprost in glaucoma and ocular hypertension in non-responder patients","volume":"10","author":"Brennan","year":"2017","journal-title":"Int J Ophthalmol"},{"key":"10.1016\/j.jtos.2024.08.001_bib128","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.2147\/OPTH.S137537","article-title":"Evaluating intraocular pressure-lowering solutions for the treatment of open-angle glaucoma: comparison between bimatoprost 0.03% and bimatoprost 0.01% - an observational switch study","volume":"11","author":"Deshpande","year":"2017","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jtos.2024.08.001_bib129","doi-asserted-by":"crossref","first-page":"557","DOI":"10.2147\/OPTH.S126042","article-title":"Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction","volume":"11","author":"Munoz Negrete","year":"2017","journal-title":"Clin Ophthalmol"},{"issue":"3","key":"10.1016\/j.jtos.2024.08.001_bib130","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1177\/112067210701700311","article-title":"Ocular symptoms and signs with preserved and preservative-free glaucoma medications","volume":"17","author":"Jaenen","year":"2007","journal-title":"Eur J Ophthalmol"},{"issue":"6","key":"10.1016\/j.jtos.2024.08.001_bib131","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1089\/jop.2013.0216","article-title":"Ocular surface changes in glaucomatous patients treated with and without preservatives beta-blockers","volume":"30","author":"Iester","year":"2014","journal-title":"J Ocul Pharmacol Therapeut"},{"issue":"3","key":"10.1016\/j.jtos.2024.08.001_bib132","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1755-3768.2010.01907.x","article-title":"Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication","volume":"88","author":"Uusitalo","year":"2010","journal-title":"Acta Ophthalmol"},{"issue":"4","key":"10.1016\/j.jtos.2024.08.001_bib133","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1136\/bjo.86.4.418","article-title":"Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication","volume":"86","author":"Pisella","year":"2002","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jtos.2024.08.001_bib134","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2147\/OPTH.S295821","article-title":"Real-world study on patient satisfaction and tolerability after switching to preservative-free latanoprost","volume":"15","author":"Erb","year":"2021","journal-title":"Clin Ophthalmol"},{"issue":"5","key":"10.1016\/j.jtos.2024.08.001_bib135","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/BF02850305","article-title":"Assessment of corneal epithelial integrity after acute exposure to ocular hypotensive agents preserved with and without benzalkonium chloride","volume":"23","author":"Whitson","year":"2006","journal-title":"Adv Ther"},{"issue":"4","key":"10.1016\/j.jtos.2024.08.001_bib136","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/BF02850039","article-title":"Comparison of the relative toxicity of travoprost 0.004% without benzalkonium chloride and latanoprost 0.005% in an immortalized human cornea epithelial cell culture system","volume":"23","author":"Yee","year":"2006","journal-title":"Adv Ther"},{"key":"10.1016\/j.jtos.2024.08.001_bib137","article-title":"Antimicrobial preservatives part three: challenges facing preservative systems","author":"Elder","year":"2012","journal-title":"Am Pharm Rev"},{"key":"10.1016\/j.jtos.2024.08.001_bib138","article-title":"Antimicrobial preservatives part two: choosing a preservative","author":"Elder","year":"2012","journal-title":"Am Pharm Rev"},{"issue":"1","key":"10.1016\/j.jtos.2024.08.001_bib139","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1089\/108076803762718097","article-title":"A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension","volume":"19","author":"Mundorf","year":"2003","journal-title":"J Ocul Pharmacol Therapeut"},{"issue":"1","key":"10.1016\/j.jtos.2024.08.001_bib140","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/01.ijg.0000212274.50229.c6","article-title":"Travoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacy","volume":"16","author":"Lewis","year":"2007","journal-title":"J Glaucoma"},{"key":"10.1016\/j.jtos.2024.08.001_bib141","first-page":"1189","article-title":"The preservative polyquaternium-1 increases cytoxicity and NF-kappaB linked inflammation in human corneal epithelial cells","volume":"18","author":"Paimela","year":"2012","journal-title":"Mol Vis"},{"issue":"6","key":"10.1016\/j.jtos.2024.08.001_bib142","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1007\/s11094-019-02038-4","article-title":"Modern preservatives of microbiological stability","volume":"53","author":"Anurova","year":"2019","journal-title":"Pharm Chem J"},{"issue":"4","key":"10.1016\/j.jtos.2024.08.001_bib143","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/ICL.0000000000000860","article-title":"Noninferiority study comparing latanoprost 0.005% without versus with benzalkonium chloride in open-angle glaucoma or ocular hypertension","volume":"48","author":"Wirta","year":"2022","journal-title":"Eye Contact Lens"},{"issue":"8","key":"10.1016\/j.jtos.2024.08.001_bib144","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1097\/01.ico.0000133997.07144.9e","article-title":"The lack of association between signs and symptoms in patients with dry eye disease","volume":"23","author":"Nichols","year":"2004","journal-title":"Cornea"},{"issue":"2","key":"10.1016\/j.jtos.2024.08.001_bib145","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/aos.12012","article-title":"Correlations between commonly used objective signs and symptoms for the diagnosis of dry eye disease: clinical implications","volume":"92","author":"Sullivan","year":"2014","journal-title":"Acta Ophthalmol"},{"issue":"7","key":"10.1016\/j.jtos.2024.08.001_bib146","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1442-9071.2012.02781.x","article-title":"Prevalence of signs and symptoms of ocular surface disease in individuals treated and not treated with glaucoma medication","volume":"40","author":"Ghosh","year":"2012","journal-title":"Clin Exp Ophthalmol"},{"issue":"9","key":"10.1016\/j.jtos.2024.08.001_bib147","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1097\/ICO.0b013e318294b0c0","article-title":"Psychometric properties and validation of the Standard Patient Evaluation of Eye Dryness questionnaire","volume":"32","author":"Ngo","year":"2013","journal-title":"Cornea"},{"issue":"1","key":"10.1016\/j.jtos.2024.08.001_bib148","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/01.ICL.0000140910.03095.FA","article-title":"Lid wiper epitheliopathy and dry eye symptoms","volume":"31","author":"Korb","year":"2005","journal-title":"Eye Contact Lens"},{"issue":"7","key":"10.1016\/j.jtos.2024.08.001_bib149","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1097\/00003226-200210000-00007","article-title":"Dry Eye Investigation (DREI) Study Group. Use of the dry eye questionnaire to measure symptoms of ocular irritation in patients with aqueous tear deficient dry eye","volume":"21","author":"Begley","year":"2002","journal-title":"Cornea"},{"issue":"8","key":"10.1016\/j.jtos.2024.08.001_bib150","first-page":"3743","article-title":"A new tool for fast assessment of ocular surface disease in glaucoma patients","volume":"58","author":"Ortiz-Perez","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"10.1016\/j.jtos.2024.08.001_bib151","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S1542-0124(12)70053-8","article-title":"Development and validation of a short global dry eye symptom index","volume":"5","author":"Schaumberg","year":"2007","journal-title":"Ocul Surf"},{"issue":"3","key":"10.1016\/j.jtos.2024.08.001_bib152","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1089\/jop.2010.0003","article-title":"In vitro toxicity of topical ocular prostaglandin analogs and preservatives on corneal epithelial cells","volume":"26","author":"Kahook","year":"2010","journal-title":"J Ocul Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.jtos.2024.08.001_bib153","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1167\/iovs.11-8775","article-title":"Corneal neurotoxicity due to topical benzalkonium chloride","volume":"53","author":"Sarkar","year":"2012","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"Pt B","key":"10.1016\/j.jtos.2024.08.001_bib154","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1007\/978-1-4615-0717-8_157","article-title":"Alternative reference values for tear film break up time in normal and dry eye populations","volume":"506","author":"Abelson","year":"2002","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"10.1016\/j.jtos.2024.08.001_bib155","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2147\/OPTH.S1496","article-title":"The challenge of dry eye diagnosis","volume":"2","author":"Savini","year":"2008","journal-title":"Clin Ophthalmol"},{"issue":"7","key":"10.1016\/j.jtos.2024.08.001_bib156","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1097\/ICO.0b013e3181930c03","article-title":"Staining patterns in dry eye syndrome: rose bengal versus lissamine green","volume":"28","author":"Machado","year":"2009","journal-title":"Cornea"},{"issue":"2","key":"10.1016\/j.jtos.2024.08.001_bib157","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1586\/erm.12.142","article-title":"TearLab\u00ae osmolarity system for diagnosing dry eye","volume":"13","author":"Versura","year":"2013","journal-title":"Expert Rev Mol Diagn"},{"issue":"11","key":"10.1016\/j.jtos.2024.08.001_bib158","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1016\/j.ophtha.2016.07.028","article-title":"Matrix metalloproteinase 9 testing in dry eye disease using a commercially available point-of-care immunoassay","volume":"123","author":"Messmer","year":"2016","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.jtos.2024.08.001_bib159","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1167\/iovs.08-2704","article-title":"Upper and lower tear menisci in the diagnosis of dry eye","volume":"50","author":"Shen","year":"2009","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"10.1016\/j.jtos.2024.08.001_bib160","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1755-3768.2011.02183.x","article-title":"Tear meniscus measurement in nasolacrimal duct obstruction patients with Fourier-domain optical coherence tomography: novel three-point capture method","volume":"90","author":"Park","year":"2012","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jtos.2024.08.001_bib161","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.exer.2017.06.010","article-title":"New insights into the morphology and function of meibomian glands","volume":"163","author":"Arita","year":"2017","journal-title":"Exp Eye Res"},{"issue":"6","key":"10.1016\/j.jtos.2024.08.001_bib162","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1167\/iovs.10-5505","article-title":"Imaging lid-parallel conjunctival folds with OCT and comparing its grading with the slit lamp classification in dry eye patients and normal subjects","volume":"52","author":"Veres","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"10.1016\/j.jtos.2024.08.001_bib163","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1136\/bjophthalmol-2017-310759","article-title":"Advances in dry eye imaging: the present and beyond","volume":"102","author":"Chan","year":"2018","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jtos.2024.08.001_bib164","author":"Jung"},{"issue":"12","key":"10.1016\/j.jtos.2024.08.001_bib165","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/IJG.0000000000001041","article-title":"Influence of treating ocular surface disease on intraocular pressure in glaucoma patients intolerant to their topical treatments: a report of 10 cases","volume":"27","author":"Dubrulle","year":"2018","journal-title":"J Glaucoma"},{"key":"10.1016\/j.jtos.2024.08.001_bib166","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/S0140-6736(18)32213-X","article-title":"Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial","volume":"393","author":"Gazzard","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.jtos.2024.08.001_bib167","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ophtha.2022.09.009","article-title":"Laser in glaucoma and ocular hypertension (LIGHT) trial","volume":"130","author":"Gazzard","year":"2023","journal-title":"Ophthalmology"}],"container-title":["The Ocular Surface"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012424000818?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542012424000818?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T01:03:54Z","timestamp":1733447034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542012424000818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":166,"alternative-id":["S1542012424000818"],"URL":"https:\/\/doi.org\/10.1016\/j.jtos.2024.08.001","relation":{},"ISSN":["1542-0124"],"issn-type":[{"value":"1542-0124","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preservatives and ocular surface disease: A review","name":"articletitle","label":"Article Title"},{"value":"The Ocular Surface","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtos.2024.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}